ArticleCell metabolism2014
APOC3, coronary disease, and complexities of Mendelian randomization.
Article in Cell metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.European heart journal · 2022Trial
- Hepatic Lipoprotein Production, Cardiometabolic Phenotypes, and Subtypes of Steatotic Liver Disease.Circulation research · 2026Review
- Article
- Hepatic targeting in ASCVD: integrating lipid lowering and inflammation modulation from statins to gene editing.Journal of translational medicine · 2026Review
- Molecular Regulation and Therapeutic Targeting of VLDL Production in Cardiometabolic Disease.Cellular and molecular gastroenterology and hepatology · 2025Review
- APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.Current atherosclerosis reports · 2023Review
- Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study.Lipids in health and disease · 2020Observational
- Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia.Annals of clinical biochemistry · 2019Review
- The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.Endocrine reviews · 2019Review
- Rare non-coding variants are associated with plasma lipid traits in a founder population.Scientific reports · 2017Article
- Leveraging human genetics to guide drug target discovery.Trends in cardiovascular medicine · 2017Review
- An APOC3 3'UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.Scientific reports · 2016Article
- Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?Current cardiology reports · 2016Review
- Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.Disease models & mechanisms · 2015Article
- Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction.PLoS genetics · 2015Article
- Inactivating mutations in NPC1L1 and protection from coronary heart disease.The New England journal of medicine · 2014Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.